Mediprist 200 mg Tablets
PDF Leaflet Revision Date: 30 September 2024
Clinical Summary
Quick overview from the medicine insert
Indication
Medical termination of intra-uterine pregnancy and cervical dilation.
Dosage (summary)
200 mg as a single dose for up to 63 days gestation; 600 mg for later terminations.
Onset of Action / Duration
Onset: 24 hours, Duration: 36-48 hours
Special Populations
- Renal failure
- Hepatic failure
- Malnutrition
Pregnancy & Breastfeeding
Contraindicated in pregnancy; avoid during breastfeeding.
Key Drug Interactions
- CYP3A4 inducers
- CYP3A4 inhibitors
Contraindications
- Hypersensitivity to mifepristone
- Chronic adrenal failure
- Ectopic pregnancy
- Unremoved IUD
Common side effects
- Nausea
- Vomiting
- Dizziness
- Vaginal bleeding
Counselling Points
- Follow-up visit mandatory
- Inform about potential heavy bleeding
- Avoid pregnancy until next cycle
Serious warnings
- Severe cutaneous adverse reactions
- Risk of incomplete abortion
Important Disclaimer
The Mediprist 200 mg Tablets professional information leaflet below is the property of Adcock Ingram and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
